SAB Biotherapeutics, Inc. – NASDAQ:SABSW

Add to watchlist

$0.028

-0.05

-64.62%

Market closed

Open in 1 day

+108.88%

month

+108.88%

quarter

+100.00%

year

Market Cap	830.63K
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-6.73

Revenue	2.60M
EBITDA	-37.11M
Income	-39.86M
Revenue Q/Q	62.54%
Revenue Y/Y	-58.89%

Profit margin	-448.01%
Oper. margin	-531.4%
Gross margin	100%
EBIT margin	-531.4%
EBITDA margin	-1426.22%

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

SAB Biotherapeutics, Inc. (NASDAQ:SABSW): Profit margin
Jun 2023	85.51K	-6.88M	-8046.13%
Sep 2023	1.26M	-5.10M	-402.59%
Dec 2023	305.01K	-22.85M	-7493.75%
Mar 2024	944.57K	-5.02M	-532.06%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW): Debt to assets
Jun 2023	35442560	15.72M	44.37%
Sep 2023	28336297	13.08M	46.16%
Dec 2023	83941253	26.64M	31.74%
Mar 2024	71371082	18.54M	25.99%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW): Cash Flow
Jun 2023	-4.89M	-22.68K	-363.78K
Sep 2023	-5.16M	-40.85K	-140.30K
Dec 2023	-13.44M	-67.86K	67.63M
Mar 2024	-10.91M	-31.35M	-227.02K

SAB Biotherapeutics alternative data

SAB Biotherapeutics, Inc. (NASDAQ:SABSW): Employee count
Aug 2023	56
Sep 2023	56
Oct 2023	56
Nov 2023	56
Dec 2023	56
Jan 2024	56
Feb 2024	56
Mar 2024	56
Apr 2024	56
May 2024	57
Jun 2024	57
Jul 2024	57

SAB Biotherapeutics
Hedge Funds Holdings Q1 2023

0.43% -3.52%

of SABSW is owned by hedge funds

5 -6

hedge funds hold SABSW stock

183.28K -1.51M

shares is hold by hedge funds

SABSW hedge funds holdings changes

SAB Biotherapeutics
Insider Trading

SAB Biotherapeutics, Inc. (NASDAQ:SABSW): Insider trades (number of shares)
Period	Buy	Sel
Oct 2021	1500	278
Sep 2022	24000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	13 Sep 2022	HAMILTON CHRISTINE E director, 10 percent owner director, 10 percent owner	Common Stock	10,000	$0.73	$7,300
Purchase	7 Sep 2022	SULLIVAN EDDIE JOE director, 10 percent owner, officer: CH.. director, 10 percent owner, off..	Common Stock	14,000	$0.74	$10,318
Sale	26 Oct 2021	BEYER RUSSELL P officer: Chief Financial Officer officer: Chief Financial Officer	Common Stock	278	$7.9	$2,196
Purchase	14 Oct 2021	REICH SAMUEL J director, 10 percent owner, officer: CEO an.. director, 10 percent owner, off..	Common Stock	1,000	$10.11	$10,110
Purchase	13 Oct 2021	KATZ ILAN director, 10 percent owner director, 10 percent owner	Common Stock	500	$10.11	$5,053
Purchase	1 Oct 2021	KATZ ILAN director, 10 percent owner director, 10 percent owner	Common Stock	1,000	$10.09	$10,090
Purchase	1 Oct 2021	SPRAGENS JEFFREY G director director	Common Stock	13,000	$10.07	$130,910
Purchase	14 Jan 2021	BIG CYPRESS HOLDINGS LLC director, 10 percent owner, offic.. director, 10 percent owner, off..	Common Stock	417,200	$10	$4,172,000
Purchase	14 Jan 2021	KATZ ILAN director, 10 percent owner director, 10 percent owner	Common Stock	417,200	$10	$4,172,000
Purchase	14 Jan 2021	REICH SAMUEL J director, 10 percent owner, officer: CEO an.. director, 10 percent owner, off..	Common Stock	417,200	$10	$4,172,000

SABSW insider trading transactions

Frequently Asked Questions (FAQ)

What's the price of SAB Biotherapeutics stock today?

One share of SAB Biotherapeutics stock can currently be purchased for approximately $0.03.
When is SAB Biotherapeutics's next earnings date?

Unfortunately, SAB Biotherapeutics's (SABSW) next earnings date is currently unknown.
Does SAB Biotherapeutics pay dividends?

No, SAB Biotherapeutics does not pay dividends.
How much money does SAB Biotherapeutics make?

SAB Biotherapeutics has a market capitalization of 830.63K and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 90.63% to 2.24M US dollars.
What is SAB Biotherapeutics's stock symbol?

SAB Biotherapeutics, Inc. is traded on the NASDAQ under the ticker symbol "SABSW".
What is SAB Biotherapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of SAB Biotherapeutics?

Shares of SAB Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does SAB Biotherapeutics have?

As Jul 2024, SAB Biotherapeutics employs 57 workers, which is 2% more then previous quarter.
When SAB Biotherapeutics went public?

SAB Biotherapeutics, Inc. is publicly traded company for more then 3 years since IPO on 25 Oct 2021.
What is SAB Biotherapeutics's official website?

The official website for SAB Biotherapeutics is sabbiotherapeutics.com.
Where are SAB Biotherapeutics's headquarters?

SAB Biotherapeutics is headquartered at 2100 East 54th Street North, Sioux Falls, SD.
How can i contact SAB Biotherapeutics?

SAB Biotherapeutics's mailing address is 2100 East 54th Street North, Sioux Falls, SD and company can be reached via phone at +60 5 679 6980.

SAB Biotherapeutics, Inc.

sabbiotherapeutics.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

SAB Biotherapeutics, Inc., a biopharmaceutical company, develops immunotherapies against infectious diseases, autoimmune diseases, and oncology. It offers SAB-142 anti-thymocyte globulin for Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). SAB Biotherapeutics, Inc. was incorporated in 2014 and is based in Sioux Falls, South Dakota with an additional office in Cambridge, Massachusetts.

+60 5 679 6980

2100 East 54th Street North
Sioux Falls, SD 33140

CIK: 0001833214
ISIN: US78397T1117
CUSIP: 78397T111